No description available.

Xanthogranulomatosis is a common dermatological disease in birds. This form of inflammation, possibly associated with lipometabolic disorders, can also be seen in visceral organs, which as yet has only rarely been described in avian medicine. In general, diseases related to impaired lipid metabolism are frequently reported in avian medicine, with hepatic steatosis and atherosclerosis being the most common. In human medicine, infectious agents—especially some strains of adenovirus—were implicated in contributing to lipometabolic disorders; this has also been described for chicken. Here, a case series of six Red-crowned Parakeets (Cyanoramphus novaezelandiae) is presented, all cases being characterized by psittacine adenovirus 2 (PsAdV-2) infection with or without disseminated xanthogranulomatosis. The affected individuals were examined alive by clinical examination. Total body radiographs were taken of two birds, haematology and blood biochemistry results were achieved in one bird. The birds either died immediately after clinical presentation or within two days, two individuals were euthanized due to worsening of their clinical condition. All birds underwent a post-mortem examination. While four birds were finally diagnosed with disseminated xanthogranulomatosis, all six individuals had large eosinophilic intranuclear inclusion bodies in the epithelial cells of the collecting ducts of the kidney and tested positive for PsAdV-2. Further examinations are needed to clarify to what extent PsAdV-2 might elicit lipometabolic disease in birds, or psittacines in general, and, in particular, the Red-crowned Parakeet.

L’allogreffe de cellules souches hématopoïétiques (CSH) est un des seuls traitements curatifs des hémopathies bénignes ou malignes et des déficits immunitaires primitifs. Cependant, les infections notamment virales ainsi que la réaction du greffon contre l’hôte comptent parmi les complications les plus fréquentes des allogreffes associées à une morbidité et une mortalité élevées. Les infections virales surviennent souvent en l’absence de reconstitution immunitaire spécifique dans un contexte d’immunosuppression liée à la GVHD elle-même ou à la prophylaxie ou au traitement de la GVHD. Les traitements médicamenteux anti-viraux préconisés présentent une efficacité inconstante dans ce contexte d’immunodéficience et ne sont pas dénués de toxicité. L’alternative thérapeutique prometteuse est l’immunothérapie adoptive cellulaire notamment celle qui consiste en l’injection de lymphocytes T spécifiques anti-viraux isolés par technique immunomagnétique (VSTs). Cependant, ces lymphocytes T peuvent être la cible des traitements immunosuppresseurs administrés pour la GVHD mais également par eux-mêmes être potentiellement la cause de la survenue ou de la réactivation d’une GVHD. Nous avons montré dans ce travail que l’efficacité des VSTs, qui repose sur leur expansion in vivo lors de la rencontre avec le virus circulant, est principalement permise par les sous-populations lymphocytaires les plus immatures, même si elles ne sont présentes qu’en faible proportion. Nous défendons dans ce travail le fait que l’efficacité des VST ainsi que leur persistance repose prioritairement sur la présence des sous-populations lymphocytaires T les plus immatures et ce quel que soit le degré de compatibilité HLA entre les VSTs et le receveur. De plus, leur sensibilité modérée aux corticoïdes, que nous avons étudiée in vitro, ne justifie pas la modulation de l’immunosuppression lors de l’injection des ADV-VSTs, comme observé in vivo dans le protocole clinique multicentrique de phase I/II que nous avons mené entre 2012 et 2015. En effet, ce protocole clinique ne rapporte aucune GVHD de novo après injection d’ADV-VSTs ; en revanche, la modulation de l’immunosuppression peut potentiellement être incriminée dans la réactivation de GVHD dans les semaines suivant l’injection des ADV-VSTs. La réalisation d’un essai comparatif de phase II permettra de prouver très clairement le rôle des VSTs dans la réactivation de GVHD. / Hematopoietic stem cell transplantation (HSCT) is one of the only curative treatments for benign or malignant hematological diseases and primary immune deficiencies. However, viral infections and graft-versus-host disease (GVHD) are among the most frequent complications after HSCT associated with high morbidity and mortality. Viral infections often occur in the absence of specific immune reconstitution in the context of immunosuppression related to GVHD itself or to the prophylaxis or treatment of GVHD. The recommended anti-viral drug treatments have an inconsistent efficacy in this context of immunodeficiency and are not devoid of toxicity. The promising therapeutic alternative is adoptive immunotherapy, in particular the infusion of specific anti-viral T lymphocytes isolated by immunomagnetic technique (VSTs). However, these T lymphocytes may be targeted by immunosuppressive treatments administered for GVHD, but also may be the cause of the onset or reactivation of GVHD. We have shown in this work that the efficacy of VSTs, which is based on their in vivo expansion when they encounter the circulating virus, is mainly allowed by the most immature lymphocyte subpopulations, even in a small proportion. We argue in this work that the efficacy of VSTs and their persistence is mainly based on the presence of the most immature T lymphocyte subpopulations and this regardless of the degree of HLA compatibility between the VSTs and the recipient. Moreover, their moderate sensitivity to corticosteroids, which we have studied in vitro, does not justify the modulation of immunosuppression at the time of infusion of ADV-VSTs, as observed in vivo in the multicenter phase I / II clinical trial we conducted between 2012 and 2015. Indeed, this clinical trial does not report any de novo GVHD after ADV-VSTs infusion. On the other hand, modulation of immunosuppression may potentially be incriminated in the reactivation of GVHD within weeks of ADV-VST infusion. A Phase II comparative trial will bring the evidence of efficacy and will clearly determine the role of VSTs in the reactivation of GVHD

Bei der Hornhauttransplantation (Keratoplastik) handelt es sich um die häufigste Transplantation humanen Gewebes. Das Hornhautendothel, eine empfindliche Zellschicht auf der Innenseite der Kornea, verfügt nicht über die Fähigkeit, Zellverluste durch Proliferation auszugleichen. Zwei grundsätzliche Probleme ergeben sich aus dieser Eigenschaft des kornealen Endothels für die Keratoplastik: ein Endothelzellverlust tritt zum einen während der Hornhautkonservierung vor Keratoplastik auf und führt zu einem Ausschluss vieler Transplantate, zum anderen ist er oftmals im Zuge von immunvermittelten Abstoßungsreaktionen oder in Folge chronischer Vorgänge nach Keratoplastik zu beobachten. Aus diesem Grund ist eine möglichst hohe Endothelzelldichte auf kornealen Transplantaten eine Voraussetzung für den Erfolg einer Keratoplastik. Das erste Ziel dieser Arbeit war deshalb die Übertragung des Gens für den aziden FGF (aFGF) in korneale Endothelzellen mit Hilfe des nicht-viralen Gentransfers. Dazu wurden verschiedene Lipid-Formulationen für den Gentransfer in humane korneale Endothelzellen in vitro optimiert. Der Einsatz von DAC-30 und Lipofectin für den aFGF-Gentransfer führte zu einer deutlichen Proliferationssteigerung (um ca. 50 %) der Zellen, womit der Einsatz dieses Wachstumsfaktors eine gute Möglichkeit darzustellen scheint, die prä-operative Ausgangssituation kornealer Transplantate zu verbessern. Der zweite Teil dieser Arbeit befasste sich mit Untersuchungen zur Immunmodulation nach Keratoplastik. Eine Hauptrolle bei der Abstoßung kornealer Transplantate spielen CD4+ T- Lymphozyten. In anderen Transplantationsmodellen konnte durch die lokale Überexpression immunmodulatorischer Zytokine die Entstehung und Aktivierung dieser Zellen gehemmt und eine verlängerte Transplantatüberlebenszeit erzielt werden. Mit Hilfe gentherapeutischer Vektoren (Adenoviren, Liposomen) wurden die immunmodulatorischen Zytokine vIL-10 und rIL-4 ex vivo in korneale Transplantate eingebracht. Nach erfolgreichen in vitro- Untersuchungen zur Genexpression wurden die transduzierten/transfizierten Hornhäute in einem starken Abstoßungsmodell der Ratte transplantiert, was jedoch zu keiner signifikanten Verlängerung der Transplantatüberlebenszeit führte. Diese Arbeit liefert Hinweise darauf, dass der lokale Gentransfer von vIL-10 in der Keratoplastik nicht für eine Immunmodulation geeignet ist, und dass sowohl die Zytokindosis, als auch der Zeitpunkt und der Ort der Vektorapplikation eine entscheidende Rolle für den Transplantationserfolg spielen. / Keratoplasty is the most common transplantation of human tissue. The corneal endothelium constitutes a damagable cell layer on the inner surface of the cornea, unable to proliferate. From this, two general problems arise for the outcome of keratoplasty: loss of corneal endothelial cells occurs on the one hand during corneal long time storage before keratoplasty and enforces the lack of donor tissue, on the other hand it is often correlated with immune mediated rejections as well as with chronic processes after keratoplasty. Therefore an endothelial cell number as high as possible on corneal grafts displays a requirement for successful keratoplasties. The first aim of this study was non-viral gene transfer of the aFGF (acidic FGF) gene in corneal endothelial cells. Different lipid formulations were optimized for gene transfer in human corneal endothelial cells in vitro. Application of DAC-30 and Lipofectin for aFGF gene transfer clearly showed a stimulating effect on cell proliferation (approximately 50 %). Thus, the use of aFGF seems to be a good possibility for improving the pre-operative situation of corneal allografts. The second part of this study deals with the immune modulation after keratoplasty. CD4+ T- lymphocytes play a key role in rejection processes after keratoplasty. Local over expression of immunomodulatory cytokines in different transplantation models could inhibit the development and activation of these cells and was able to prolong the allograft survival time. Using different gene therapeutic vectors (adenoviruses, liposomes) the immunomodulatory cytokines vIL-10 and rIL-4 were transferred ex vivo in corneal allografts. After successfully determined gene expression in vitro, the transduced/transfected corneal allografts were transplanted in a strong rejection model of the rat. However, this was not sufficient in prolonging the graft survival time significantly. This study provides indications, that local gene transfer of vIL-10 in keratoplasty is not suitable for an immune modulation, and that both cytokine dose as well as time point and site of vector application play an important role for successful transplantation.

<p>Prostate cancer is one leading cause of cancer-related death among men in Western countries. The standard therapies for localized prostate cancer include radical prostatectomy and radiation therapy. Such measures are relatively effective in the short term, but many patients ultimately relapse. These patients may benefit from a combination of standard therapy and oncolytic virus therapy. My work aimed to develop viruses for this purpose.</p><p>TARP is a protein that in males is specifically expressed in prostate epithelial and cancer cells. In my thesis, I characterized the TARP promoter and showed that TARP expression is regulated at the transcriptional level by testosterone through binding of the androgen receptor in the proximal TARP promoter. I further developed TARP promoter-based regulatory sequences for prostate-specific gene expression. A sequence comprising a PSA enhancer, a PSMA enhancer and the TARP promoter was constructed and designated PPT. An adenoviral vector containing the PPT sequence shielded from transcriptional interference by an H19 insulator showed high prostate-specific transcriptional activity in human cells both in the presence and absence of testosterone. However, in experimental murine prostate cancer the PPT sequence is not active. Therefore, a two-step transcriptional amplification (TSTA) system was used together with the PPT sequence to develop an adenovirus that confers prostate-specific transgene expression also in murine cells.</p><p>I constructed a conditionally replicating adenovirus where the E1A gene expression is controlled by an H19 insulator-shielded PPT regulatory sequence, Ad[I/PPT-E1A]. This virus exhibited absolute prostate specificity in terms of E1A expression, viral replication and cytolysis <i>in vitro</i> and <i>in vivo</i>. Importantly, our virus is active both in the presence and absence of testosterone, which may prove beneficial for patients treated by hormonal withdrawal. </p><p>Hopefully, my work will improve existing gene therapy strategies for prostate cancer and in the long term improve the prognosis for patients with prostate cancer.</p>

Prostate cancer is one leading cause of cancer-related death among men in Western countries. The standard therapies for localized prostate cancer include radical prostatectomy and radiation therapy. Such measures are relatively effective in the short term, but many patients ultimately relapse. These patients may benefit from a combination of standard therapy and oncolytic virus therapy. My work aimed to develop viruses for this purpose. TARP is a protein that in males is specifically expressed in prostate epithelial and cancer cells. In my thesis, I characterized the TARP promoter and showed that TARP expression is regulated at the transcriptional level by testosterone through binding of the androgen receptor in the proximal TARP promoter. I further developed TARP promoter-based regulatory sequences for prostate-specific gene expression. A sequence comprising a PSA enhancer, a PSMA enhancer and the TARP promoter was constructed and designated PPT. An adenoviral vector containing the PPT sequence shielded from transcriptional interference by an H19 insulator showed high prostate-specific transcriptional activity in human cells both in the presence and absence of testosterone. However, in experimental murine prostate cancer the PPT sequence is not active. Therefore, a two-step transcriptional amplification (TSTA) system was used together with the PPT sequence to develop an adenovirus that confers prostate-specific transgene expression also in murine cells. I constructed a conditionally replicating adenovirus where the E1A gene expression is controlled by an H19 insulator-shielded PPT regulatory sequence, Ad[I/PPT-E1A]. This virus exhibited absolute prostate specificity in terms of E1A expression, viral replication and cytolysis in vitro and in vivo. Importantly, our virus is active both in the presence and absence of testosterone, which may prove beneficial for patients treated by hormonal withdrawal. Hopefully, my work will improve existing gene therapy strategies for prostate cancer and in the long term improve the prognosis for patients with prostate cancer.

No description available.

L’identification d’antiviraux à large spectre est un des défis majeurs de la rechercheactuelle en virologie. Une des stratégies les plus prometteuses consiste à cibler une interactionvirus/hôte conservée. Ainsi, avec la technique d’AlphaScreen® et le modèle d’interactionprotéine VI de l’Adénovirus (AdV)/Nedd4-2, nous avons réalisé un criblage biochimique àhaut débit contre l’interaction virus/hôte [LP]PxY/Nedd4, commune à différentes familles devirus. Nous avons trouvé des candidats inhibiteurs issus d’une banque de composés approuvéspar les agences de santé. Nous les avons testés, caractérisés et validé leur effet antiviral surdeux familles de virus totalement différentes. Ainsi, les composés C9 (Sulconazole) et C4(Flunarizine) que nous avons identifiés diminuent la réplication de l’AdV, un virus à ADNenveloppé et du virus de Marburg, un virus à ARN, non enveloppé de la famille desFiloviridae. Ces résultats ont permis de valider l’interaction [LP]PxY/Nedd4 comme unecible idéale d’un antiviral à large spectre et de proposer un repositionnement de ces moléculesC9 et C4 comme antiviraux potentiels. Nous avons également synthétisé de nouvellesmolécules analogues du composé C9 et démontré qu’elles étaient tout aussi efficaces que lecomposé lui-même sur la réplication de l’AdV. Ces résultats nous ont permis de présenter laclasse des dérivés imidazolés comme structure de base pour l’élaboration de nouveauxantiviraux, potentiellement à large spectre. / Broad-spectrum antiviral identification is considered as one of the major aims of theactual virology research and one strategy consists in targeting virus/host interaction. Using theAlphaScreen® technology and the adenoviral model protein VI/Nedd4-2, we performed highthroughputbiochemical screening targeting the [LP]PxY/Nedd4 interaction, a commoninteraction of different virus families. We identified candidate inhibitors from a librarycompound approved by health agencies. We tested, characterized and validated the antiviraleffect of those compounds on two very different virus families. Indeed, compounds C9(Sulconazole) and C4 (Flunarizine) decrease replication of the adenovirus, a DNA nonenvelopedvirus and the replication of the Marburg virus, an RNA enveloped virus from theFilovirus family. Taken together, those results permit us to validate the [LP]PxY/Nedd4interaction as good target for a broad spectrum antiviral and to propose the “repositioning” ofcompounds C4 and C9 as antivirals. Moreover, we have synthesized new analogues from C9showing similar effect on AdV replication compared to the original molecule (C9). Inconclusion, our work on developing new broad-spectrum antivirals highlights the possibilityto use imidazole derivatives as a new class of antiviral compounds.

No description available.

Systemic administration of adenovirus type 5 (Ad5) vectors for the treatment of cancer is limited by poor circulation kinetics and inefficient uptake from the bloodstream into tumours. This study reports a novel method for linkage of highly-PEGylated gold nanoparticles (AuPEG) to Ad5 by a single reduction cleavable bond. The resulting ‘dandelion’ structure provides very effective steric shielding with only minimal and reversible modification of the Ad5 capsid. This ablates in vitro cell infection, improves protection against the binding of antibodies, and enhances in vivo circulation kinetics. Focused ultrasound is a promising technology for the non-invasive, targeted treatment of cancer. In the context of drug delivery, cavitational energy generated upon exposure of ultrasound contrast agents to focused ultrasound can be used as a powerful stimulus to move therapeutics over distances of hundreds of microns away from blood vessels. In addition to providing a platform for effective stealthing, conjugation of AuPEG to Ad5 also increases the effective density of Ad5. This increase in density imparts a second major advantage on the strategy, observed for the first time in the present study: denser particles are transported significantly farther by cavitation-induced microstreaming than identically-sized particles of lower density. Specifically, in in vitro tests using a tumour-mimicking flow-channel phantom model and in in vivo experiments using tumour bearing mice, Ad5–AuPEG was delivered farther from vessels in response to ultrasound induced cavitation than either naked Ad5 or polymer-coated Ad5. The enhancements in stealthing and improvements in response to ultrasound provided by this strategy enabled up to 12% (S.D. 0.97) of the injected dose to be deposited in the tumour, compared to just 0.12% (S.D. 0.05) for Ad5 without ultrasound (p < 0.001). Consequently, in a survival study, mice treated with Ad5–AuPEG with focussed ultrasound had the slowest tumour growth and longest survival rate when compared to mice treated with Ad5 alone, Ad5–AuPEG alone, or Ad5 with focussed ultrasound. These results provide compelling evidence that the combination of focussed ultrasound with density-augmented stealthed Ad5 results in improved delivery to tumours and therapeutic efficacy. This combination of ultrasound with particle modification for optimal cavitation-mediated delivery has the potential to be applied to a broad range of anti-cancer nano-medicines and therapeutics to augment their bio-availability for improved cancer treatment.